Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: erlotinib|DRUG: Fulvestrant|DRUG: Placebo
Sponsor: University of Arkansas
Collaborators: OSI Pharmaceuticals